Floatz logo

Ixekizumab

Psoriatic Arthritis

NHS Greater Glasgow and Clydemonoclonal_antibodyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Psoriatic Arthritis cohort.

Asset / SponsorPhaseRating
Tirzepatide
JULIO GRANADOS MONTIEL
Phase 4BBB
Naltrexone
Brigham and Women's Hospital
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 1CC
Nivolumab
National Cancer Institute (NCI)
Phase 1CC
Bms-907351
National Cancer Institute (NCI)
Phase 1CC
Guselkumab
University of California, San Diego
D
Guselkumab
University of California, San Diego
N/AD
Metformin
University of Alexandria
N/AD

Same molecule, other indications

Ixekizumab is also rated in:

psoriasisDormant
BB
Indicative ·
67 / 100
View asset →
obesity disorderDormant
B
Indicative ·
56 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →